3.4 C
New York
Tuesday, January 31, 2023

Cassava Sciences Inc. (SAVA) Is Not Likely To Be The Same Tomorrow

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Cassava Sciences Inc. (SAVA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.06, or 0.21%, to $28.88. The Cassava Sciences Inc. has recorded 6,406 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Stocks Info

Cassava Sciences Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $28.82 and fluctuated between $29.71 as its day high and $27.92 as its day low. The current market capitalization of Cassava Sciences Inc. is $1.23B. A total of 0.86 million shares were traded on the day, compared to an average of 1.26M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, SAVA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 14 BUYs and 4 SELLs from insiders. Insiders purchased 308,319 shares during that period but sold 83,313.

In the most recent transaction, Barry Richard bought 36,159 shares of SAVA for 23.79 per share on Aug 23. After the transaction, the Director now owns 186,159 company shares. In a previous transaction on Aug 23, Kupiec James William bought 2,500 shares at 24.44 per share. SAVA shares that Chief Clinical Dev. Officer owns now total 2,500.

Among the insiders who bought shares, Schoen Eric acquired of 2,500 shares on Aug 12 at a per-share price of $19.95. This resulted in the Chief Financial Officer holding 19,800 shares of SAVA after the transaction. In another insider transaction, ROBERTSON SANFORD bought 100,000 shares at $20.69 per share on Aug 12. Company shares held by the Director now total 1,024,765.


The reasons why investors prefer dividend-paying companies are that dividends generate immediate cash flow and indicate that the company will perform well in the future. SAVA’s most recent ex-dividend date was 12/13/2012 when it declared a $5.25 quarterly dividend that was paid in cash on 12/24/2012.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for SAVA in the last 3 months, the mean price target is $69.75 with high estimates of $124.00 and low estimates of $11.00. In terms of 52-week highs and lows, SAVA has a high of $62.49 and a low of $13.84.

As of this writing, SAVA has an earnings estimate of -$0.48 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.38 per share and a lower estimate of -$0.59. The company reported an EPS of -$0.44 in the last quarter, which was -7.30% lower than expectations of -$0.41.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SAVA is Buy with a score of 3.00. A total of 2 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles